These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 11150165)

  • 1. Development of new hydroxamate matrix metalloproteinase inhibitors derived from functionalized 4-aminoprolines.
    Natchus MG; Bookland RG; De B; Almstead NG; Pikul S; Janusz MJ; Heitmeyer SA; Hookfin EB; Hsieh LC; Dowty ME; Dietsch CR; Patel VS; Garver SM; Gu F; Pokross ME; Mieling GE; Baker TR; Foltz DJ; Peng SX; Bornes DM; Strojnowski MJ; Taiwo YO
    J Med Chem; 2000 Dec; 43(26):4948-63. PubMed ID: 11150165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of matrix metalloproteinase inhibitors guided by molecular modeling. Picking the S(1) pocket using conformationally constrained inhibitors.
    Hanessian S; MacKay DB; Moitessier N
    J Med Chem; 2001 Sep; 44(19):3074-82. PubMed ID: 11543676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases.
    Pikul S; McDow Dunham KL; Almstead NG; De B; Natchus MG; Anastasio MV; McPhail SJ; Snider CE; Taiwo YO; Chen L; Dunaway CM; Gu F; Mieling GE
    J Med Chem; 1999 Jan; 42(1):87-94. PubMed ID: 9888835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids.
    Sawa M; Kiyoi T; Kurokawa K; Kumihara H; Yamamoto M; Miyasaka T; Ito Y; Hirayama R; Inoue T; Kirii Y; Nishiwaki E; Ohmoto H; Maeda Y; Ishibushi E; Inoue Y; Yoshino K; Kondo H
    J Med Chem; 2002 Feb; 45(4):919-29. PubMed ID: 11831904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships.
    Duan JJ; Chen L; Wasserman ZR; Lu Z; Liu RQ; Covington MB; Qian M; Hardman KD; Magolda RL; Newton RC; Christ DD; Wexler RR; Decicco CP
    J Med Chem; 2002 Nov; 45(23):4954-7. PubMed ID: 12408705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beta-aryl-succinic acid hydroxamates as dual inhibitors of matrix metalloproteinases and tumor necrosis factor alpha converting enzyme.
    Kottirsch G; Koch G; Feifel R; Neumann U
    J Med Chem; 2002 May; 45(11):2289-93. PubMed ID: 12014967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based design and synthesis of a series of hydroxamic acids with a quaternary-hydroxy group in P1 as inhibitors of matrix metalloproteinases.
    Jacobson IC; Reddy PG; Wasserman ZR; Hardman KD; Covington MB; Arner EC; Copeland RA; Decicco CP; Magolda RL
    Bioorg Med Chem Lett; 1998 Apr; 8(7):837-42. PubMed ID: 9871551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A quantitative structure-activity relationship study of hydroxamate matrix metalloproteinase inhibitors derived from functionalized 4-aminoprolines.
    Gupta SP; Kumar D; Kumaran S
    Bioorg Med Chem; 2003 May; 11(9):1975-81. PubMed ID: 12670648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Broad spectrum matrix metalloproteinase inhibitors: an examination of succinamide hydroxamate inhibitors with P1 C alpha gem-disubstitution.
    Curtin ML; Garland RB; Davidsen SK; Marcotte PA; Albert DH; Magoc TJ; Hutchins C
    Bioorg Med Chem Lett; 1998 Jun; 8(12):1443-8. PubMed ID: 9873367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of new carboxylic acid-based MMP inhibitors derived from functionalized propargylglycines.
    Natchus MG; Bookland RG; Laufersweiler MJ; Pikul S; Almstead NG; De B; Janusz MJ; Hsieh LC; Gu F; Pokross ME; Patel VS; Garver SM; Peng SX; Branch TM; King SL; Baker TR; Foltz DJ; Mieling GE
    J Med Chem; 2001 Mar; 44(7):1060-71. PubMed ID: 11297453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-Aryl sulfonyl homocysteine hydroxamate inhibitors of matrix metalloproteinases: further probing of the S(1), S(1)', and S(2)' pockets.
    Hanessian S; Moitessier N; Gauchet C; Viau M
    J Med Chem; 2001 Sep; 44(19):3066-73. PubMed ID: 11543675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and molecular modeling study of iminodiacetyl monohydroxamic acid derivatives as MMP inhibitors.
    Santos MA; Marques SM; Tuccinardi T; Carelli P; Panelli L; Rossello A
    Bioorg Med Chem; 2006 Nov; 14(22):7539-50. PubMed ID: 16875829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent and selective 2-naphthylsulfonamide substituted hydroxamic acid inhibitors of matrix metalloproteinase-13.
    Tommasi RA; Weiler S; McQuire LW; Rogel O; Chambers M; Clark K; Doughty J; Fang J; Ganu V; Grob J; Goldberg R; Goldstein R; Lavoie S; Kulathila R; Macchia W; Melton R; Springer C; Walker M; Zhang J; Zhu L; Shultz M
    Bioorg Med Chem Lett; 2011 Nov; 21(21):6440-5. PubMed ID: 21937229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MMP-13 selective alpha-sulfone hydroxamates: identification of selective P1' amides.
    Fobian YM; Freskos JN; Barta TE; Bedell LJ; Heintz R; Kassab DJ; Kiefer JR; Mischke BV; Molyneaux JM; Mullins P; Munie GE; Becker DP
    Bioorg Med Chem Lett; 2011 May; 21(10):2823-5. PubMed ID: 21493063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.
    Yamamoto M; Tsujishita H; Hori N; Ohishi Y; Inoue S; Ikeda S; Okada Y
    J Med Chem; 1998 Apr; 41(8):1209-17. PubMed ID: 9548812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The design, synthesis, and structure-activity relationships of a series of macrocyclic MMP inhibitors.
    Steinman DH; Curtin ML; Garland RB; Davidsen SK; Heyman HR; Holms JH; Albert DH; Magoc TJ; Nagy IB; Marcotte PA; Li J; Morgan DW; Hutchins C; Summers JB
    Bioorg Med Chem Lett; 1998 Aug; 8(16):2087-92. PubMed ID: 9873491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel series of highly selective inhibitors of MMP-3.
    Whitlock GA; Dack KN; Dickinson RP; Lewis ML
    Bioorg Med Chem Lett; 2007 Dec; 17(24):6750-3. PubMed ID: 18029177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of cyclic inhibitors of matrix metalloproteinases and TNF-alpha production.
    Xue CB; He X; Roderick J; DeGrado WF; Cherney RJ; Hardman KD; Nelson DJ; Copeland RA; Jaffee BD; Decicco CP
    J Med Chem; 1998 May; 41(11):1745-8. PubMed ID: 9599225
    [No Abstract]   [Full Text] [Related]  

  • 19. Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.
    Aranapakam V; Grosu GT; Davis JM; Hu B; Ellingboe J; Baker JL; Skotnicki JS; Zask A; DiJoseph JF; Sung A; Sharr MA; Killar LM; Walter T; Jin G; Cowling R
    J Med Chem; 2003 Jun; 46(12):2361-75. PubMed ID: 12773041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The design and synthesis of aryl hydroxamic acid inhibitors of MMPs and TACE.
    Levin JI
    Curr Top Med Chem; 2004; 4(12):1289-310. PubMed ID: 15320727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.